• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡博替尼治疗继发的一种罕见皮肤不良反应。

A rare cutaneous adverse effect secondary to cabozantinib therapy.

作者信息

Growcott Siona, Banner Alexandra, Bray Adam, Hilman Serena

机构信息

Department of Oncology, Bristol Haematology and Oncology Centre, Horfield Road, Bristol, UK.

Department of Dermatology, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, UK.

出版信息

Oxf Med Case Reports. 2018 Nov 26;2018(12):omy105. doi: 10.1093/omcr/omy105. eCollection 2018 Dec.

DOI:10.1093/omcr/omy105
PMID:30487990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6252307/
Abstract

Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient with metastatic renal cell cancer who experienced such cutaneous toxicity.

摘要

卡博替尼是一种酪氨酸激酶抑制剂，越来越多地用于治疗转移性肾细胞癌。使用这类药物时，诸如手足红斑感觉异常的皮肤毒性并不少见。然而，大疱性皮肤反应并不常见，我们报告了一例发生这种皮肤毒性的转移性肾细胞癌患者的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/c83e2c48f3c0/omy105f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/44c0d8fb49c2/omy105f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/62dc27968c7d/omy105f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/ed081d0333e5/omy105f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/c83e2c48f3c0/omy105f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/44c0d8fb49c2/omy105f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/62dc27968c7d/omy105f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/ed081d0333e5/omy105f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa41/6252307/c83e2c48f3c0/omy105f04.jpg

相似文献

1
A rare cutaneous adverse effect secondary to cabozantinib therapy.卡博替尼治疗继发的一种罕见皮肤不良反应。
Oxf Med Case Reports. 2018 Nov 26;2018(12):omy105. doi: 10.1093/omcr/omy105. eCollection 2018 Dec.
2
Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.与酪氨酸激酶抑制剂卡博替尼相关的皮肤不良反应。
JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.
3
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.卡博替尼对比依维莫司治疗晚期肾细胞癌（METEOR）：一项随机、开放标签、III 期临床试验的最终结果。
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
4
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).在接受聚乙二醇化脂质体阿霉素治疗的乳腺癌患者中使用止汗剂预防手足红斑性感觉异常（SAKK 92/08）
Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005. Epub 2014 Mar 20.
5
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.卡博替尼对比舒尼替尼作为低危或中危转移性肾细胞癌患者的初始靶向治疗：联盟A031203 CABOSUN试验
J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14.
6
Gemcitabine-induced skin necrosis.吉西他滨诱导的皮肤坏死。
SAGE Open Med Case Rep. 2018 Oct 30;6:2050313X18809268. doi: 10.1177/2050313X18809268. eCollection 2018.
7
Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.手足红斑性感觉异常：依维莫司的一种罕见不良反应。
Indian J Med Paediatr Oncol. 2016 Apr-Jun;37(2):116-8. doi: 10.4103/0971-5851.180143.
8
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.卡博替尼用于转移性乳腺癌：一项II期安慰剂对照随机停药研究的结果
Breast Cancer Res Treat. 2016 Nov;160(2):305-312. doi: 10.1007/s10549-016-4001-y. Epub 2016 Oct 6.
9
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.卡博替尼用于治疗进展性转移性甲状腺髓样癌。
Expert Rev Clin Pharmacol. 2016;9(1):69-79. doi: 10.1586/17512433.2016.1102052. Epub 2015 Nov 4.
10
Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.多西他赛相关的手足红斑性感觉异常：一例病例报告及文献综述
J Oncol Pharm Pract. 2014 Feb;20(1):73-80. doi: 10.1177/1078155213475466. Epub 2013 Mar 11.

引用本文的文献

1
Severe intertrigo resembling acquired acrodermatitis enteropathica unmasking zinc deficiency in a patient on cabozantinib therapy.严重擦烂红斑类似获得性肠病性肢端皮炎，揭示卡博替尼治疗患者的锌缺乏
JAAD Case Rep. 2025 Feb 24;59:28-30. doi: 10.1016/j.jdcr.2024.10.041. eCollection 2025 May.
2
Cabozantinib Cutaneous Toxicity-Comprehensive Review.卡博替尼皮肤毒性——综述
Life (Basel). 2025 Jan 9;15(1):72. doi: 10.3390/life15010072.

本文引用的文献

1
Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.与酪氨酸激酶抑制剂卡博替尼相关的皮肤不良反应。
JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.
2
Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.与化疗相关的手足红斑性感觉异常及其治疗
Case Rep Oncol. 2011 Apr 11;4(1):229-35. doi: 10.1159/000327767.
3
In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption.固定型药疹演变过程中表皮内CD8 + T细胞和CD4 + T细胞的体内动态变化
Br J Dermatol. 2008 Jun;158(6):1230-8. doi: 10.1111/j.1365-2133.2008.08516.x. Epub 2008 Mar 20.
4
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.聚乙二醇化脂质体阿霉素相关手足综合征：国际专家小组的建议
Eur J Cancer. 2008 Apr;44(6):781-90. doi: 10.1016/j.ejca.2008.01.028. Epub 2008 Mar 10.
5
Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.舒尼替尼：掌跖红细胞生成性大疱性感觉异常、甲周红斑和粘膜炎的一个病因。
Arch Dermatol. 2008 Jan;144(1):123-5. doi: 10.1001/archderm.144.1.123.
6
Fixed drug eruptions. Incidence, recognition, and avoidance.固定性药疹。发病率、识别与避免
Am J Clin Dermatol. 2000 Sep-Oct;1(5):277-85. doi: 10.2165/00128071-200001050-00003.